FrontPoint Named As Recipient Of Insider Info

Nov 3 2010 | 3:03am ET

FrontPoint Partners is the, until now, unidentified hedge fund that allegedly received inside information from a French doctor charged yesterday by U.S. authorities.

According to the Securities and Exchange Commission's complaint, Yves Benhamou used his position as an adviser to pharmaceutical company Human Genome to pass confidential information on the results of a hepatitis-C drug trial to at least six hedge funds. Those six hedge funds sold 6 million shares of Human Genome in December 2007 and January 2008 while in possession of confidential, negative information about those drug trials, the SEC said.

FrontPoint, which is being spun off from Morgan Stanley, sold all 3.3 million shares of Human Genome it owned in the first quarter of 2008, although it is unclear when the hedge fund sold those shares. Human Genome broke the bad news about the drug testing on Jan. 23, 2008, sending its stock price plummeting 44%.

FrontPoint has not been charged with any wrongdoing, although it has placed Chip Skowron, the co-portfolio manager of its health care hedge funds, on leave until the investigation is resolved. FrontPoint said it was "cooperating fully" with the authorities.

Benhamou was arrested on Monday in Boston on two criminal charges.


In Depth

Kettera Q&A: The Advantages of Alternative Investment Platforms

Oct 28 2016 | 5:52pm ET

The past several years have seen a distinct push towards easier and cheaper access...

Lifestyle

Trump Attends 'Villains and Heroes' Costume Party Dressed As...Himself

Dec 5 2016 | 11:16pm ET

U.S. President-elect Donald Trump attended a "Villains and Heroes" costume party...

Guest Contributor

Nowhere to Hide: Why the Future of Asset Management Depends on Innovation

Nov 15 2016 | 6:55pm ET

Information technology has reshaped the asset management industry’s periphery,...

 

From the current issue of

Chicago-based independent futures brokerage and clearing firm R.J. O’Brien & Associates (RJO) has hired industry veteran Daniel Staniford as Executive Director, responsible for the firm’s institutional business development in New York and London.

AVAILABLE NOW at BARNES & NOBLE

NEWSTAND LOCATOR